Appco Pharma Prazosin 2mg Capsules Recall - Nitrosamine Impurity
Summary
FDA has classified a Class II voluntary recall initiated by Appco Pharma LLC for Prazosin Hydrochloride Capsules, USP 2mg due to a cGMP deviation involving detection of N-nitroso-prazosin impurity C (NNP) above acceptable limits. The recall affects 5 lots totaling 58,896 bottles distributed nationwide in the U.S. The affected product was manufactured for Biocon Pharma Inc. and includes lots expiring through May 2027.
What changed
FDA classified a Class II voluntary recall for Prazosin Hydrochloride Capsules, USP 2mg (NDC 70377-067-11) initiated by Appco Pharma LLC. The recall was triggered by detection of N-nitroso-prazosin impurity C exceeding acceptable limits, constituting a cGMP deviation. Five lots are affected with expiration dates from March 2026 through May 2027.
Healthcare providers and patients with this medication should contact their pharmacy for return/replacement instructions. Pharmacies and distributors holding affected lots should verify inventory against the specified lot numbers and follow standard recall procedures for pharmaceutical products.
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Appco Pharma LLC
Drug Recalls (Class II)
← All Drug Recalls (Class II) Class II D-0420-2026 · 20260408 · Ongoing · Voluntary: Firm initiated
Product
Prazosin Hydrochloride Capsules, USP, 2mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-067-11.
Reason for Recall
cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits.
Affected Lot Numbers / Codes
Lot:2404153UC, Exp.: 2026/MAR; 2404154UC, Exp.:2026/MAR; 2502055UC, Exp.: 2027/JAN; 2505173UC, Exp.: 2027/MAY; 2505175UC, Exp.: 2027/MAY.
Quantity
58,896 bottles- 100's count
Firm Notification Method
Distribution
U.S.A. Nationwide
Initiated
20260327
FDA Classified
20260331
Product Registration
Brand: PRAZOSIN HYDROCHLORIDE
Manufacturer: Biocon Pharma Inc.
Application: ANDA213406
NDC: 70377-066, 70377-067, 70377-068
Drug Label Context (from openFDA)
The following is from the manufacturer's FDA-approved drug label, not recall-specific. Provided for context.
Indications & Usage
INDICATIONS AND USAGE Prazosin hydrochloride capsules is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cess...
Dosage & Administration
DOSAGE AND ADMINISTRATION The dose of Prazosin hydrochloride capsules should be adjusted according to the patient's individual blood pressure response. The following is a guide to its administration: Initial Dose 1 mg two or three times a day (see WARNINGS.) Maintenance Dose Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses. The therapeutic dosages most commonly employed have ranged from 6 mg to 15 mg daily given in divided doses. Doses higher than 20 mg usually do not increase efficacy, however a few patients may benefit from further increases up to a dai...
Contraindications
CONTRAINDICATIONS Prazosin hydrochloride capsules are contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients.
Warnings
WARNINGS As with all alpha-blockers, Prazosin hydrochloride capsules may cause syncope with sudden loss of consciousness. In most cases, this is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe tachycardia with heart rates of 120 to 160 beats per minute. Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in associat...
Adverse Reactions
ADVERSE REACTIONS Clinical trials were conducted on more than 900 patients. During these trials and subsequent marketing experience, the most frequent reactions associated with Prazosin hydrochloride capsules therapy are: dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpitations 5.3%, and nausea 4.9%. In most instances, side effects have disappeared with continued therapy or have been tolerated with no decrease in dose of drug. Less frequent adverse rea...
Drug Interactions
Drug Interactions Prazosin hydrochloride capsules has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides–digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives– chlordiazepoxide, diazepam, and phenobarbital; (4) antigout–allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol (see WARNINGS howev...
How Supplied
HOW SUPPLIED Prazosin Hydrochloride Capsules, USP are available containing prazosin hydrochloride, USP equivalent to 1 mg, 2 mg, or 5 mg of prazosin. The 1 mg capsule is a hard gelatin capsule with white opaque body and white opaque cap imprinted with “AC” on cap and ‘540’ on body in black ink filled with white to off white powder. They are available as follows: bottles of 100 capsules (NDC 703...
Related changes
Get daily alerts for FDA Drug Recalls (Class II)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from FDA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when FDA Drug Recalls (Class II) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.